We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

95 hedge funds and large institutions have $853M invested in Avidity Biosciences in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $739M → $853M (+$114M)

1.64% more ownership

Funds ownership: 90.15% → 91.8% (+1.6%)

5% less funds holding

Funds holding: 100 → 95 (-5)

14% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 29

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
95
Holders Change
-5
Holders Change %
-5%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
12
Increased
25
Reduced
29
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$18.1M
2
MWNA
Marshall Wace North America
New York
+$7.83M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$3.97M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.63M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$5.49M
2
ACM
Alethea Capital Management
Washington
-$5.1M
3
AWA
Aaron Wealth Advisors
Illinois
-$4.2M
4
Goldman Sachs
Goldman Sachs
New York
-$3.98M
5
SCM
Soleus Capital Management
Connecticut
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$4.79M -$3.98M -171,184 -47%
ACM
27
Altium Capital Management
New York
$4.66M +$233K +10,000 +6%
CS
28
Candriam SCA
Luxembourg
$3.95M +$3.27M +140,491 +721%
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$3.86M +$3.63M +156,047 New
Charles Schwab
30
Charles Schwab
California
$3.53M -$17.4K -746 -0.5%
AG
31
Artal Group
Luxembourg
$3.52M – – –
WP
32
Woodline Partners
California
$3.16M – – –
N
33
Nuveen
North Carolina
$2.92M +$507K +21,804 +23%
Citigroup
34
Citigroup
New York
$2.58M +$654K +28,119 +37%
Morgan Stanley
35
Morgan Stanley
New York
$2.52M -$1.26M -54,357 -35%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$2.33M +$232K +9,965 +12%
Wells Fargo
37
Wells Fargo
California
$1.65M -$478K -20,532 -24%
Los Angeles Capital Management
38
Los Angeles Capital Management
California
$1.49M -$139K -5,990 -9%
ACP
39
Acuta Capital Partners
California
$1.48M -$512K -22,000 -27%
Principal Financial Group
40
Principal Financial Group
Iowa
$1.19M +$575K +24,706 +105%
Rafferty Asset Management
41
Rafferty Asset Management
New York
$1.19M -$291K -12,508 -21%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$1.03M -$98.5K -4,232 -9%
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$969K +$363K +15,600 +66%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$927K +$163K +6,985 +23%
Swiss National Bank
45
Swiss National Bank
Switzerland
$919K +$174K +7,500 +25%
Bank of America
46
Bank of America
North Carolina
$788K +$4.86K +209 +0.7%
PP
47
PDT Partners
New York
$689K +$649K +27,900 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$683K +$111K +4,752 +21%
SG Americas Securities
49
SG Americas Securities
New York
$680K -$70.6K -3,033 -10%
Squarepoint
50
Squarepoint
New York
$580K +$253K +10,875 +86%
1
2
3 4 5

RNAM Hedge Fund Activity: Q2 2021 in Review

95 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2021, worth a combined $853M — up 15% from $739M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RNAM and 12 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 25 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $18.1M. The largest seller was Cormorant Asset Management, cutting an estimated $5.49M.

  • 95 institutional investors held Avidity Biosciences (RNAM) as of Q2 2021, down from 100 in Q1 2021.
  • Funds reported $853M of Avidity Biosciences stock for Q2 2021, up 15% quarter-over-quarter.
  • 12 funds opened new Avidity Biosciences positions in Q2 2021 and 17 closed out, a net change of -5 holders.
  • The largest Avidity Biosciences buyer in Q2 2021 was T. Rowe Price Associates, an estimated $18.1M added.
  • The largest Avidity Biosciences seller in Q2 2021 was Cormorant Asset Management, an estimated $5.49M sold.

Based on aggregated 13F filings for Q2 2021.